Stomach cancer (credit: canva)
Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).
A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:
1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.
2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.
3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.
4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.
5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding
There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.
Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.
1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.
2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.
3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.
He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.
Credit: AI
Men in the UK could face limited access to prostate cancer testing under updated guidance that gives GPs authority to decide if some men without symptoms should receive a PSA blood test.
The development comes after the UK Government rejected calls for routine prostate cancer screening for all men. It instead backed a targeted approach in which those at highest genetic risk would be considered first.
Under existing NHS guidance, men aged 50 and over can request a PSA test after discussing the benefits and limitations with their GP.
The new guidance states that the decision to authorise PSA testing ultimately rests with the doctor. Recent reports suggested that the policy has sparked criticism from cancer charities and campaigners.
Regardless, a PSA test can find prostate cancer, but it cannot reliably tell doctors which cancers are dangerous and which may be manageable with treatment.
The UK National Screening Committee (UK NSC) concluded in May that routine screening of the whole male population could do more harm than good.
It said that for every 1,000 men aged 50 to 60 screened using PSA, up to two lives could be saved, but as many as 20 men could experience overdiagnosis.
Also read: Prostate Cancer: NHS England's New Precision Radiotherapy Offers Hope In Just 5 Sessions
The UK NSC has recommended targeted screening every two years for a much smaller group who are more likely to get prostate cancer. It includes men in the age group of 45 to 61 who have a BRCA2 gene variant and a family history of breast, ovarian, pancreatic or prostate cancer.
Importantly, the committee did not recommend targeted screening for other groups at higher risk, including Black men or men with a family history but no BRCA2 variant. It said that more evidence is needed to take a call on those matters.
PSA, or prostate-specific antigen, is a protein produced by prostate cells. Higher levels can be associated with prostate cancer. But they can also increase because of non-cancerous prostate enlargement or inflammation.
This means screening can produce false alarms and lead to biopsies or treatment that some men may never need. Cancer Research UK says PSA testing may also fail to detect some prostate cancers.
Also read: Testicular Cancer Warning: Be Vigilant About These Unnoticeable Signs, Doctor Warns
Black men have a substantially higher risk of developing and dying from prostate cancer, but the UK NSC said there is currently insufficient evidence to establish whether routine screening of Black men would help.
At the same time, the UK Government has expanded access for Black men to the TRANSFORM prostate cancer screening trial, which is designed to find a better way of detecting clinically significant prostate cancer.
The change does not mean PSA testing is being banned. Men with symptoms or particular risk factors can still be assessed by their GP, and doctors can request testing when it is clinically appropriate.
Credit: AI
The Ebola outbreak in the Democratic Republic of Congo (DRC) is expanding at a rapid pace. According to a senior United Nations humanitarian official, the virus now estimated to be claiming one life every 30 minutes.
Tom Fletcher, UN Under-Secretary-General for Humanitarian Affairs and Emergency Relief Coordinator, issued the warning on August 14, calling for urgent international response as the outbreak continues to overwhelm communities and health systems in the Democratic Republic of Congo.
“The outbreak is the fastest growing on record,” Fletcher said, according to reports, urging the international community to step up support.
The latest warning comes as the outbreak has crossed a grim milestone. According to Reuters, DRC had recorded 4,449 confirmed Ebola cases and 2,061 deaths as of August 11.
The outbreak was officially declared in mid-May, but WHO has since found evidence that transmission may have started months earlier. Early patients were reportedly misdiagnosed with illnesses such as malaria or typhoid, allowing the virus to spread before Ebola was identified.
Currently, the virus has also moved far beyond its epicentre in Ituri province. WHO reported in July that cases had spread across five provinces and 46 health zones, with the outbreak concentrated in Ituri but also affecting North Kivu, South Kivu, Haut-Uele and Tshopo.
More recent reporting indicates that the outbreak has now reached a sixth province, while more than 2,100 deaths have been reported.
Also read: Ebola 2026 Outbreak Spreading Faster Than Any Before, On Track To Become Deadliest: WHO Chief
Apart from an overwhelmed healthcare system, conflict, uncontrolled population displacement, poor infrastructure, lack of protective equipment and mistrust of health authorities are making it harder for health workers to identify contacts and reach patients. Health workers have also gone on strike due to nonpayment of wages, which has further weakened the response.
Reports suggested that 60% to 70% of newly detected infections are occurring outside known contact chains, a crucial sign that indicates contact tracing is struggling to keep up with transmission.
Also read: Ebola Death Toll Tops 2,000 In DRC: New Study Reveals Likely Source Of Bundibugyo Virus Outbreak
The widely used Ervebo vaccine targets the Zaire variant of Ebola, not Bundibugyo virus. WHO says there is currently no licensed vaccine or specific treatment for Bundibugyo virus, although several candidates are now being investigated.
WHO experts have recently recommended a clinical trial to determine whether Ervebo could provide some protection against Bundibugyo, after encouraging results in animal studies.
Meanwhile, clinical trials of potential vaccines and treatments are underway in affected areas.
Despite the challenges, WHO chief Dr Tedros Adhanom Ghebreyesus said significant progress has been made towards containing and eradicating the virus. It includes:
Credit: AI
Kenya recently approved seven semaglutide-based drugs, expanding access to a class of drugs that has rapidly moved from diabetes treatment to one of the most talked-about weight-management therapies.
The Pharmacy and Poisons Board (PPB) said the medicines were assessed by regulatory authorities for quality, safety, and effectiveness. The move adds new options as demand for GLP-1 drugs continues to rise in the country.
Kenya already had Novo Nordisk’s Ozempic and Wegovy in the market. The five newly registered generic semaglutide products have been approved for treating and managing type 2 diabetes. A generic product called Truglyx was also launched in Nairobi in July.
An important thing to remember considering using these drugs is that even though they have the same active ingredient, it does not mean these medicines can be used interchangeably.
“While these products contain the same active ingredient, their approved uses are not necessarily interchangeable and must be understood with reference to the indication approved for each product,” PPB Chief Executive Officer Dr Ahmed Mohamed said.
Also read: GLP-1 Weight Loss Drugs Ozempic, Wegovy, Mounjaro Tied To Over 60 Reported Deaths In Australia
Although Ozempic and Wegovy contain the same active ingredient, they are not simply two names for the same treatment.
Ozempic is approved for adults with type 2 diabetes whose blood sugar is not adequately controlled, alongside diet and physical activity.
Wegovy is intended to be used for weight management in adults with a high BMI, alongside diet and exercise.
That is why the PPB has warned patients against assuming that all semaglutide products can be substituted for one another.
“While these products contain the same active ingredient, their approved uses are not necessarily interchangeable,” PPB Chief Executive Officer Dr Ahmed Mohamed said.
The regulator has also stressed that semaglutide medicines are prescription-only drugs and should be used only after assessment and prescription by a qualified healthcare professional.
Also read: UK Woman Dies After Sudden Abdominal Pain Following Increase In Her Mounjaro Dose
The drugs have become popular for their ability to reduce appetite and help lose weight. But the effects of these drugs extend way beyond the weighing scale.
A 2026 analysis of the SELECT trial found semaglutide was associated with fewer hospital admissions and shorter hospital stays among people with overweight or obesity and cardiovascular disease who did not have diabetes.
At the same time, the rapid expansion of the market means there will be more competition. South Africa’s regulator was reviewing 12 generic semaglutide applications in July after patent expiry opened the door to generic competition.
Brazil also approved five new injectable semaglutide medicines last month, showing that manufacturers are rapidly responding to growing demand of GLP-1 drugs.
Just as GLP-1 medicines are steadily gaining popularity, reports emerged stating that semaglutide had the highest number of reported deaths with suspected associations, followed by Tirzepatide, Liraglutide and Dulaglutide.
62 deaths in Australia have been reported to the medicines regulator, the Therapeutic Goods Administration (TGA), with suspected associations with GLP-1 medicines, including Ozempic, Wegovy and Mounjaro.
The TGA has also received reports of nearly 3,000 serious adverse events involving these medicines, which are used by hundreds of thousands of Australians, The Herald Sun reported.
Reported adverse reactions include nausea, pancreatitis, suicidal thoughts and a rare eye condition that can cause blindness.
© 2024 Bennett, Coleman & Company Limited